STP 251G
Alternative Names: STP-251GLatest Information Update: 15 Sep 2022
At a glance
- Originator Sirnaomics
- Class Antianaemics; Antihyperlipidaemics; Peptide drug conjugates; Small interfering RNA
- Mechanism of Action Apolipoprotein C-III inhibitors; TMPRSS6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haemochromatosis; Hypertriglyceridaemia
Most Recent Events
- 06 Sep 2022 Preclinical trials in Haemochromatosis in USA (SC) before September 2022 (Sirnaomics pipeline, September 2022)
- 06 Sep 2022 Preclinical trials in Hypertriglyceridaemia in USA (SC) before September 2022 (Sirnaomics pipeline, September 2022)